Advanced therapeutic approach in management of diabetes mellitus through precision medicine

Among chronic diseases, diabetes mellitus carries one of the most life-threatening and disabling complications. It has its cost complications in addition to reducing life expectancy. Diabetes management aims to find each patient’s best course of action at the ideal time. Using precision medicine for patients with diabetes mellitus can improve the quality of therapy. For this, genetic screening becomes an essential component. The pharmacogenetics of antidiabetic medications can be a hallmark component that can be incorporated into genetic screening. For the management of diabetes, precision medicine is gaining momentum. Long-lasting response to oral sulphonylureas in insulin-dependent infants because of neonatal diabetes (abnormal beta cells) is considered one of the best examples of the significance of precision medicine. The present review aims to pinpoint the new subgroups of diabetes based on glutamic acid decarboxylase antibodies, age, body mass index, A1C, insulin resistance and glycemic response to metformin. Incorporating genetic screening into therapeutic therapy and achieving precision medicine for type 2 diabetes patients depends on the pharmacogenetics of anti-diabetic drugs. The importance of PM in the treatment of diabetes is expanding and its use can revolutionize the lives of diabetic individuals.